Yahoo
NSE - Delayed Quote INR

Hikal Limited (HIKAL.NS)

220.74 +9.16 (+4.33%)
At close: 3:29:58 PM GMT+5:30
Chart Range Bar
Loading chart for HIKAL.NS
  • Previous Close 211.58
  • Open 213.88
  • Bid --
  • Ask --
  • Day's Range 207.00 - 222.52
  • 52 Week Range 146.25 - 261.00
  • Volume 651,678
  • Avg. Volume 1,543,949
  • Market Cap (intraday) 27.217B
  • Beta (5Y Monthly) 0.53
  • PE Ratio (TTM) --
  • EPS (TTM) -2.74
  • Earnings Date (est.) --
  • Forward Dividend & Yield 0.60 (0.28%)
  • Ex-Dividend Date Sep 4, 2026
  • 1y Target Est 300.00

Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, biotechnology, life sciences, animal health, crop protection, and specialty chemicals industries. The company operates in two segments, Pharmaceuticals and Crop Protection. It provides anti-convulsant, anti-inflammatory, analgesic, anti-parasitic, anti-lipemic, anti-histaminic, anti-depressant, anti-psychotic, anti-emetic, anti-diabetic, anti-thrombotic, anti-viral, and haemorheologic products; animal health products, such as anti-tick, anti-parasitic, analgesic, anabolic steroids, female sex hormone, insecticide, and NSAID; and specialty biocides and antimicrobial actives, as well as additives for leather, paint coatings, paper, water treatment, personal care, building materials, and textile industries. The company also manufactures pesticides and herbicides, including diuron tech, temephos tech, thiacloprid tech, clothianidin tech, dichloroaniline, N-bromosuccinimide, prothioconazole technical, trifloxystrobin technical, and BIT. In addition, it engages in contract research, custom synthesis, and custom manufacturing of intermediates and active pharmaceutical ingredients. The company operates in India, the United States, Canada, Europe, South East Asia, and internationally. The company was formerly known as Hikal Chemical Industries Ltd. and changed its name to Hikal Limited in April 2000. Hikal Limited was incorporated in 1988 and is based in Navi Mumbai, India.

www.hikal.com

2,152

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

HIKAL.NS
2.43%
S&P BSE SENSEX (^BSESN)
11.18%

1-Year Return

HIKAL.NS
7.15%
S&P BSE SENSEX (^BSESN)
9.82%

3-Year Return

HIKAL.NS
19.89%
S&P BSE SENSEX (^BSESN)
18.12%

5-Year Return

HIKAL.NS
58.10%
S&P BSE SENSEX (^BSESN)
26.09%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY27
Revenue 4B
Earnings -74M
Profit Margin -1.85%

Q1

FY26

Q2

FY26

Q3

FY26

Q1

FY27

0
1B
2B
3B
4B
-10.0%
-8.0%
-6.0%
-4.0%
-2.0%

Analyst Insights

View More

Analyst Price Targets

300.00
300.00 Average
220.74 Current
300.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -1.95%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    17.35B

  • Net Income Avi to Common (ttm)

    -338M

  • Diluted EPS (ttm)

    -2.74

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    138M

  • Total Debt/Equity (mrq)

    57.04%

  • Levered Free Cash Flow (ttm)

    --

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: